Four years ago, a report that a common species of fungus might fuel pancreatic cancer offered a promising new view of the deadly disease.
Ascidian Therapeutics raises $40m to advance drug development
Ascidian’s lead programme is an RNA exon editor, which can potentially prevent the progression of ABCA4 retinopathies. Credit: fizkes / Shutterstock.com. Ascidian Therapeutics has raised $40m
November 9, 2023